The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 3, 1999, Pages 357-361

  Stoa Birketvedt G ^a   Florholmen, J ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; OLSALAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLITIS, ULCERATIVE; COLON; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED;

EID: 0033055298     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00483.x     Document Type: Article

References (16)

1. 1 Peppercorn MA. Sulphasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 1984; 101: 77-86.
2. 2 Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-6.
3. 3 Ruf-Ballauf W, Hofstädter F, Krentz K. Akute interstitielle nephritis durch 5-aminosalicylsäure? Internist 1989; 30: 262-4.
4. 4 Novis BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Gut 1988; 296: 1442.
5. 5 Dick AP, Grayson MJ. Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 438-42.
6. 6 SAS Institute Inc. In: SAS STAT User's Guide, Vol. 2, 4th edn. Version 6. Cary, NC. SAS Institute Inc., 1989: 846.
7. 7 Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992; 33: 563-4.
8. 8 Henning HV, Meinhold J, Eisenhauer T, Scheler F, Gröhne HJ. Chronische interstitielle nephritis nach behandlung mit 5-aminosalicylsäure. Dtsch Med Wochenschr 1989; 114: 1091.
9. 9 Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-6.
10. 10 Tremaine WJ, Schroeder KW. Urinary sediment abnormalities in patients on long-term oral 5-aminosalicylic acid (5-ASA) for chronic ulcerative colitis (CUC). Gastroenterology 1988; 94: 465.
11. 11 Tsamis D, Macpherson A, Forgac I, et al. Urine enzyme profiles as indicators of renal tubular dysfunction in inflammatory bowel disease (IBD). Gut 1992; 33(Suppl. 1): W34.
12. 12 Onstad GR, Abraham PA. Urinary N-acetyl-β-D-glucosaminidase (NAG) during oral 5-aminasalicylic acid (5-ASA) therapy for ulcerative colitis. Clin Pharmacol Ther 1990; 47: 175.
13. 13 Riley SA, Lloyd D, Mani V. Test for renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992; 33: 1348-52.
14. 14 Diener U, Tuczek HV, Fischer C, Maier K, Klotz U. Test for renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Arch Pharmacol 1984; 326: 278-82.
15. 15 Biddle W, Miner PB. Evaluation of potential nephrotoxicity of oral 5-ASA treatment of patients with ulcerative colitis. Gastroenterol 1989; 96: A44(Abstract).
16. 16 Schreiber S, Raedler A, Howaldt S, Zehnter W, Daerr WH, Kruis W. 5-Aminosalicylate related renal dysfunction in IBD. Gut 1994; 35(Suppl. 4): A27(Abstract).